# Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.

Source: https://onco.cc/trials/nct03401294/  
OnCo record `nct03401294` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by University of Saskatchewan, now recruiting.

## Summary

Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. is a phase 2, interventional study registered as NCT03401294 by University of Saskatchewan, with a registry enrolment figure of 32 participants, started 2025-05-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: FOLFOXIRI and Bevacizumab. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Rate of liver metastasectomy. Colorectal eligibility wording from the registry: "* Adult patients, aged between 18 and 70 years with histologically proven adenocarcinoma or poorly differentiated carcinoma of the colon and rectum with unresectable liver-only metastases and no extra-hepatic disease". Sites: Canada. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: CONVERSION
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT03401294
- Phase: 2
- Setting: Conversion From Unresectable To Resectable Liver Metastases In Patients With Liver-Only Metastatic Colorectal Cancer Treated With FOLFOXIRI Plus Bevacizumab. The Conversion Trial.
- Sponsor: University of Saskatchewan
- Enrolled: 32

## Sources

- ClinicalTrials.gov NCT03401294: https://clinicaltrials.gov/study/NCT03401294

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct03401294.json